Verge Genomics Closes $4M in Seed Financing

vergeVerge Genomics, a San Francisco, CA-based biopharmaceutical company focused on neurodegenerative diseases, closed $4m in seed financing.

The round was led by IA Ventures with participation from Two Sigma Ventures, Draper Associates, Great Oaks VC, Slow Ventures, Karlin Venture, Elad Gil and David Lee.

The company intends to use the funds to expand development on its algorithmic platform while advancing several existing lead candidates through further preclinical proof of concept experiments.

Founded by Alice Zhang, President and Chief Executive Officer, and Jason Chen, CSO, and launched through YCombinator’s accelerator program, Verge focuses on accelerating drug development for neurodegenerative diseases, such as Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), and Parkinson’s Disease, utilizing its proven network algorithms, which can analyze thousands of datasets to predict which drugs will work.



Join the discussion